Panitumumab Brand Name– Vectibix
What is Panitumumab
Panitumumab is an epidermal growth factor receptor (EGFR) antagonist and a human IgG2 kappa monoclonal antibody, produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Panitumumab is FDA approved as monotherapy and in combination with chemotherapy for the treatment of patients with wild-type RAS metastatic colorectal cancer.
It differs from cetuximab in that it has a higher affinity for the EGFR receptor and has a lower incidence of hypersensitivity reactions.
Dermatologic adverse reactions are common, occurring in up to 90% (grade 3 or 4, 15%) of patients treated with panitumumab as monotherapy.
Patients who develop dermatologic toxicities should be monitored closely for inflammatory or infectious sequelae. Severe infusion-related reactions may also occur; monitor vital signs closely during and after administration
Indications
- colorectal cancer
For the treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer
for the first-line treatment of wild-type RAS (both KRAS and NRAS) metastatic colorectal cancer in combination with FOLFOX4
Side Effects
- abdominal pain
- acne vulgaris
- acne vulgaris
- acneiform rash
- acneiform rash
- alopecia
- angioedema
- anorexia
- anorexia
- antibody formation
- asthenia
- asthenia
- bronchospasm
- bullous rash
- chills
- conjunctivitis
- conjunctivitis
- cough
- cough
- dehydration
- dehydration
- diarrhea
- diarrhea
- dyspnea
- dyspnea
- epistaxis
- erythema
- erythema
- exfoliative dermatitis
- exfoliative dermatitis
- fatigue
- fatigue
- fever
- flushing
- GI obstruction
- hypertrichosis
- hypocalcemia
- hypokalemia
- hypokalemia
- hypomagnesemia
- hypomagnesemia
- hypotension
- infection
- infection
- infusion-related reactions
- infusion-related reactions
- keratitis
- nausea
- nausea
- necrotizing fasciitis
- palmar-plantar erythrodysesthesia (hand and foot syndrome)
- palmar-plantar erythrodysesthesia (hand and foot syndrome)
- paresthesias
- photosensitivity
- pneumonitis
- pruritus
- pruritus
- pulmonary embolism
- pulmonary fibrosis
- rash
- rash
- renal failure (unspecified)
- skin erosion
- skin necrosis
- skin ulcer
- skin ulcer
- Stevens-Johnson syndrome
- stomatitis
- stomatitis
- thrombosis
- toxic epidermal necrolysis
- vomiting
- vomiting
- weight loss
- weight loss
- xerosis
- xerosis
- xerostomia
Monitoring Parameters
- serum electrolytes
Contraindications
- acute bronchospasm
- breast-feeding
- contraception requirements
- electrolyte imbalance
- fever
- geriatric
- hamster protein hypersensitivity
- hypocalcemia
- hypokalemia
- hypomagnesemia
- hypotension
- infection
- infertility
- infusion-related reactions
- keratitis
- KRAS mutations
- ocular disease
- pneumonitis
- pregnancy
- pulmonary disease
- pulmonary fibrosis
- reproductive risk
- sepsis
- serious rash
- skin disease
- sunlight (UV) exposure
Interactions
- Bevacizumab
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
